Development of AE147 Peptide-Conjugated Nanocarriers for Targeting uPAR-Overexpressing Cancer Cells

PURPOSE: An AE147 peptide-conjugated nanocarrier based on PEGylated liposomes was developed in order to target the metastatic tumors overexpressing urokinase-type plasminogen activator receptor (uPAR), which cancer progression via uPA signaling. Therefore, the AE147 peptide-conjugated nanocarrier sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, June Yong, Shin, Yuseon, Won, Woong Roeck, Lim, Chaemin, Kim, Jae Chang, Kang, Kioh, Husni, Patihul, Lee, Eun Seong, Youn, Yu Seok, Oh, Kyung Taek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367088/
https://www.ncbi.nlm.nih.gov/pubmed/34408417
http://dx.doi.org/10.2147/IJN.S315619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367088/
https://www.ncbi.nlm.nih.gov/pubmed/34408417
http://dx.doi.org/10.2147/IJN.S315619

Ejemplares similares